Dasatinib-Induced Pulmonary Arterial Hypertension Treated with Upfront Combination Therapy
Pulmonary arterial hypertension (PAH) is a rare complication of dasatinib that was approved as a first-line therapy for chronic myelocytic leukemia (CML). A 24-year-old man presenting dyspnea at rest and leg edema was admitted to our hospital. He had been diagnosed with CML and prescribed dasatinib...
Saved in:
Main Authors: | Makoto Nishimori, Tomoyuki Honjo, Kenji Kaihotsu, Naohiko Sone, Sachiko Yoshikawa, Junichi Imanishi, Kazuhiko Nakayama, Noriaki Emoto, Masanori Iwahashi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-01-01
|
Series: | Case Reports in Cardiology |
Online Access: | http://dx.doi.org/10.1155/2018/3895197 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Haemorrhagic Colitis Caused by Dasatinib
by: Nishant Patodi, et al.
Published: (2012-01-01) -
Association between the prognosis and comorbidity of active cancer in chronic thromboembolic pulmonary hypertension
by: Hiroyuki Fujii, et al.
Published: (2025-01-01) -
Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy
by: Ninna Aggerholm-Pedersen, et al.
Published: (2016-01-01) -
Upfront Radiotherapy with Concurrent and Adjuvant Vismodegib Is Effective and Well-Tolerated in a Patient with Advanced, Multifocal Basal Cell Carcinoma
by: Abigail I. Franco, et al.
Published: (2018-01-01) -
A logistic regression model to predict long-term survival for borderline resectable pancreatic cancer patients with upfront surgery
by: Jin-Can Huang, et al.
Published: (2025-02-01)